Workflow
开立医疗: 董事会薪酬与考核委员会关于公司2025年限制性股票与股票期权激励计划相关事项的核查意见

Core Viewpoint - The company has conducted a review of its 2025 restricted stock and stock option incentive plan, confirming its eligibility to implement the plan in accordance with relevant laws and regulations [2][3][4]. Group 1: Eligibility for Implementation - The company does not fall under any disqualifying conditions for implementing the stock incentive plan as outlined in the relevant regulations [2]. - The company has not received any negative or unqualified audit opinions on its financial reports for the last fiscal year [2]. - There have been no instances of improper profit distribution in the last 36 months [2]. Group 2: Qualification of Incentive Objects - The identified incentive objects do not include independent directors, supervisors, foreign employees, or shareholders holding more than 5% of the company's shares [3]. - All selected incentive objects meet the qualifications set forth in the Company Law and other relevant regulations [3]. - The company will publicly disclose the names and positions of the incentive objects for at least 10 days prior to the shareholders' meeting [3]. Group 3: Compliance and Benefits of the Plan - The drafting and review process of the incentive plan complies with all relevant laws and regulations, ensuring no harm to the interests of the company and its shareholders [4]. - The plan does not involve any financial assistance or guarantees to the incentive objects [4]. - The implementation of the incentive plan aims to establish a long-term incentive mechanism, attract and retain talent, and align the interests of shareholders, the company, and employees [4].